Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
08 Avril 2024 - 12:15PM
Business Wire
Company estimates $15 million of milestone
payments in the first quarter
Organon (NYSE: OGN), a global healthcare company with a focus on
women’s health, will release its first quarter 2024 financial
results on May 2, 2024, prior to the company’s webcast and
conference call scheduled for 8:30 a.m. EDT.
IPR&D and Milestones
Organon currently expects that it will record approximately $15
million of milestone payments in the first quarter of 2024,
representing approximately $0.05 to both GAAP and non-GAAP earnings
per share. The milestone payments relate to progress associated
with the development of a denosumab biosimilar candidate and expect
to be paid in accordance with certain agreements with Shanghai
Henlius Biotech, Inc., one of Organon’s biosimilar
collaborators.
As previously disclosed, Organon does not forecast IPR&D (in
process research and development) or milestone payments due to the
level of uncertainty and ability to forecast the timing of such
achievements. As such, this payment, as well as any future
IPR&D and milestone payments are not contemplated in the
company’s financial guidance provided on February 15, 2024.
Organon’s first quarter 2024 results have not been finalized and
are subject to the company’s quarterly financial statement closing
procedures. There can be no assurance that actual results will not
differ from the preliminary estimates described herein.
Accessing First Quarter 2024 Financial Results
Webcast:
Interested parties may access the live call via webcast on the
Organon website at
https://www.organon.com/investor-relations/events-and-presentations/.
A replay of the webcast will be available approximately two hours
after the conclusion of the live event on the company’s
website.
Institutional investors and analysts interested in participating
in the call must register in advance by clicking on this link:
https://registrations.events/direct/Q4I58511
Following registration, participants will receive a confirmation
email containing details on how to join the conference call,
including dial-in information and a unique passcode and registrant
ID. Pre-registration will allow participants to bypass an operator
and be placed directly into the call.
About Organon
Organon is a global healthcare company formed to focus on
improving the health of women throughout their lives. Organon
offers more than 60 medicines and products in women’s health in
addition to a growing biosimilars business and a large franchise of
established medicines across a range of therapeutic areas.
Organon’s existing products produce strong cash flows that support
investments in innovation and future growth opportunities in
women’s health and biosimilars. In addition, Organon is pursuing
opportunities to collaborate with biopharmaceutical innovators
looking to commercialize their products by leveraging its scale and
presence in fast growing international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 10,000 employees with headquarters located in Jersey
City, New Jersey.
For more information, visit http://www.organon.com and connect
with us on LinkedIn, Instagram, X (formerly known as Twitter) and
Facebook.
Cautionary Note Regarding Forward-Looking Statements
The information above reflects management’s current intentions
and expectations for the future with respect to Organon’s
anticipated charges for milestone payments and the related impact
to Organon’s GAAP and non-GAAP earnings per share, which constitute
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements are subject to a number of risks,
assumptions, uncertainties and other factors, such as the
completion of Organon’s quarter-end closing process, including
review by management and the audit committee of the Organon’s board
of directors, which could result in material changes to the
preliminary estimates described herein. Organon undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Factors that could cause results to differ materially from those
described in the forward-looking statements can be found in
Organon’s filings with the Securities and Exchange Commission
("SEC"), including Organon’s most recent Annual Report on Form 10-K
and subsequent SEC filings, available at the SEC’s Internet site
(www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408210237/en/
Organon Media Contacts:
Karissa Peer (614) 314-8094
Kate Vossen (732) 675-8448
Organon Investor Contacts:
Jennifer Halchak (201) 275-2711
Alex Arzeno (203) 550-3972
Organon (NYSE:OGN)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Organon (NYSE:OGN)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024